ERAS

ERAS is undergoing a 'High-Conviction Price Discovery' phase, effectively decoupled from the broader 'Caution' macro regime. The catalyst is structural: a successful $258M upsized equity offering at $10.00 cleared the funding overhang, allowing institutions to aggressively reprice the company's 'pan-RAS' pipeline (specifically ERAS-0015) without dilution risk. The +130% monthly move confirms that capital is rotating into high-quality, idiosyncratic biotech stories as a hedge against broader AI/Tech volatility.